Clinical Trial

The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 9, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder. Given that LPP, EDP, and melasma are all disorders of pigmentation with dermal involvement, it is possible that tranexamic acid can also reduce pigmentation in LPP and EDP as well.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-01-16; most recent amendment 2026-03-12.
Status change: Recruiting → Completed 2026-03-12
Status change: Not Yet Recruiting → Recruiting 2020-03-17
Trial Details
NCT Number NCT04233749
Lead Sponsor Henry Ford Health System
Conditions Lichen Planus Pigmentosus, Erythema Dyschromicum Perstans, Ashy Dermatosis of Ramirez
Enrollment 5 participants
Start Date 2020-03-17
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-09